Skip to main content
×
×
Home
  • Print publication year: 2010
  • Online publication date: February 2011

Chapter 22 - Ethno-psychopharmacology

from Section 4 - Management, services and training
Summary
This chapter uses existing epidemiological data on the elderly to illustrate differences between migrant elders and the native ones. The relationship between migration and mental health in older people within the context of the UK is examined in the domains of demography, epidemiology of mental disorders and suicide in old age, access to services and potential ways forward to improve service access. In the UK, migrants are often referred to as black and minority ethnic (BME) individuals. The total number of elderly from all BME groups combined was 531909. The two most common mental disorders in old age are dementia and depression. The anticipated increase in psychiatric morbidity has enormous implications for the design, development and delivery of culturally capable, appropriate and sensitive Old Age Psychiatry Services (OAPSs) for BME elders. Over the past decade, the mental health of BME groups has become a national priority in the UK.
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Migration and Mental Health
  • Online ISBN: 9780511760990
  • Book DOI: https://doi.org/10.1017/CBO9780511760990
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

Allen, J. J., Rack, P. H., Vaddadi, K. S. (1977). Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgraduate Medical Journal, 53(4), 79–86.
Arranz, M. J., Kapur, S. (2008). Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophrenia Bulletin, 34(6), 1130–44.
Arranz, M. J., Munro, J., Sham, P. et al. (1998). Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research, 32, 93–9.
Bijl, M. J., Visser, L. E., Hofman, A. et al. (2008). Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. British Journal of Clinical Pharmacology, 65(4), 558–64.
Brown, C., Schulberg, H. C., Sacco, D., Perel, J. M., Houck, P. R. (1999). Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African American and white patients. Journal of Affective Disorders, 53, 185–92.
Chaudhry, I. B., Neelam, K., Duddu, V., Husain, N. (2008). Ethnicity and psychopharmacology. Journal of Psychopharmacology, 22, 673–80.
Comas-Díaz, L., Jacobsen, F. M. (1991). Ethnocultural transference and countertransference in the therapeutic dyad. American Journal of Orthopsychiatry, 61(3), 392–402.
Connolly, A., Taylor, D. (2008). Ethnicity and quality of prescribing among in-patients in south London. British Journal of Psychiatry, 193, 161–2.
de Leon, J., Armstrong, S. C., Cozza, K. L. (2005a). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–73.
de Leon, J., Susce, M. T., Pan, R. M. et al. (2005b). The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Journal of Clinical Psychiatry, 66, 15–27.
Dettling, M., Cascorbi, I., Opgen-Rhein, C., Schaub, R. (2007). Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. The Pharmacogenomics Journal, 7, 325–32.
Fukuda, T., Nishida, Y., Zhou, Q. et al. (2000). The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. European Journal of Clinical Pharmacology, 56(2), 175–80.
Hariri, A. R., Mattay, V. S., Tessitore, A. et al. (2002). Serotonin transporter genetic variations and the response of the human amygdala. Science, 297(5580), 400–3.
Health Survey for England 1999 (2001). The Health of Minority Ethnic Groups, London: The Stationery Office.
Heils, A., Teufel, A., Petri, S. et al. (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry, 66, 2621–4.
Herbeck, D. M., West, J. C., Ruditis, I. et al. (2004). Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatric Services, 55, 677–84.
Hong Ng, C., Norman, T. R., Naing, K. O. et al. (2006). A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. International Clinical Psychopharmacology, 21, 87–92.
Hu, W. H., Lee, C. F., Yang, Y. Y., Tseng, Y. T. (1983). Imipramine plasma levels and clinical response. Bulletin of Chinese Social Neuroscience and Psychiatry, 9, 40–9.
Israili, Z. H., Dayton, P. G. (2001). Human alpha-1-glycoprotein and its interaction with drugs. Drug Metabolism Reviews, 33(2), 161–235.
Jones, D. S., Perlis, R. H. (2006). Pharmacogenetics, race and psychiatry: prospects and challenges. Harvard Review of Psychiatry, 14, 92–108.
Kim, H., Lim, S. W., Kim, S. et al. (2006). Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. Journal of the American Medical Association, 296, 1609–18.
Kirchheiner, J., Nickchen, K., Bauer, M. et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9, 442–73.
Kuno, E., Rothbard, A. B. (2002). Racial disparities in antipsychotic prescribing prescription patterns for patients with schizophrenia. American Journal of Psychiatry, 159, 567–72.
Lambert, T., Norman, T. R. (2008). Ethnic differences in psychotropic drug response and pharmacokinetics. In C. H. Ng, K-M. Lin, B. S. Singh and E. Chiu (eds) Ethno-Psychopharmacology: Advances in Current Practice. Cambridge: Cambridge University Press, 38–61.
Lee, S. (1993). Side effects of chronic lithium therapy in Hong Kong Chinese: an ethnopsychiatric perspective. Culture Medicine and Psychiatry, 17(3), 301–20.
Lehman, A. F., Steinwachs, D. M. (1998). Patterns of usual care for schizophrenia: initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophrenia Bulletin, 24(1), 11–20.
Lesch, K. P., Bengel, D., Heils, A. et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274, 1527–31.
Lieberman, J. A., Yunis, J., Egea, E. et al. (1990). Agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47, 945–8.
Lin, K. M., Finder, E. (1983). Neuroleptic dosages for Asians. American Journal of Psychiatry, 140(4), 490–1.
Lin, K. M., Lau, J. K., Smith, R. et al. (1988). Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology, 96, 365–9.
Lin, K. M., Poland, R. E., Nuccio, I. et al. (1989). A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. American Journal of Psychiatry, 146(10), 1307–11.
Lin, K. M., Chen, C. H., Yu, S. H., Wang, S. C. (2008). Culture and ethnicity in psychopharmacotherapy. In C. H. Ng, K-M. Lin, B. S. Singh and E. Chiu (eds) Ethno-Psychopharmacology: Advances in Current Practice. Cambridge: Cambridge University Press, 27–37.
Luo, N. (2004). Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore. Human Psychopharmacology, 19, 259–64.
Marcos, L. R., Cancro, R. C. (1982). Pharmacotherapy of Hispanic depressed patients: clinical observations. American Journal of Psychotherapy, 36, 505–13.
McMahon, F. J., Buervenich, S., Charney, D. et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics, 78(5), 804–14.
Melkersson, K. I., Scordo, M, G., Gunes, A., Dahl, M. L. (2007). Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. Journal of Clinical Psychiatry, 68, 697–704.
Mills, E., Montori, V. M., Wu, P. et al. (2004). Interaction of St John’s wort with conventional drugs: a systematic review of clinical trials. British Medical Journal, 329(7456), 27–30.
Morgenstern, H., Glazer, W. M. (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Archives of General Psychiatry, 50(9), 723–33.
Mori, A., Maruo, Y., Iwai, M., Sato H., Takeuchi, Y. (2005). UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metabolism and Disposition, 33, 672–5.
Munro, J., O’Sullivan, D., Andrews, C. et al. (1999). Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. British Journal of Psychiatry, 175, 576–80.
Ng, C. H., Klimidis, S. (2008). Cultural factors and the use of psychotropic medications. In C. H. Ng, K.-M. Lin, B. S. Singh and E. Chiu (eds) Ethno-Psychopharmacology: Advances in Current Practice. Cambridge: Cambridge University Press, Chapter 10.
Ng, C. H., Schweitzer, I., Norman, T., Easteal, S. (2004). The emerging role of pharmacogenetics: implications for clinical psychiatry. Australian and New Zealand Journal of Psychiatry, 38(7), 483–9.
Ng, C. H., Chong, S. A., Lambert, T. et al. (2005). An inter-ethnic comparision study of clozapine dosage, clinical response and plasma levels. International Clinical Psychopharmacology, 20(3), 163–8.
Ng, C. H., Easteal, S., Tan, S. et al. (2006). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(5), 953–7.
Pi, E. H., Tran-Johnson, T. K., Walker, N. R. et al. (1989). Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacology Bulletin, 25, 483–7.
Poolsup, N., Li Wan Po, A., Knight, T. L. (2000). Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics, 25(3), 197–220.
Ray, W. A., Hall, K., Meador, K. G. (2007). Racial differences in antidepressant treatment preceding suicide in a Medicaid population. Psychiatric Services, 58(10), 1317–23.
Schweitzer, I. (2008). Introduction. In C. H. Ng, K-M. Lin, B. S. Singh and E. Chiu (eds) Ethno-Psychopharmacology: Advances in Current Practice. Cambridge: Cambridge University Press, 1–4.
Serretti, A., Malitas, P. N. Mandelli, et al. (2004). Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis for mood disorders. The Pharmacogenomics Journal, 4, 267–73.
Sinha, M., Larkin, E. K., Elston, R. C., Redline, S. (2006). Self-reported race and genetic admixture. New England Journal of Medicine, 354, 421–2.
Stahl, S. M. (2008). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press.
Stewart-Williams, S., Podd, J. (2004). The placebo effect: dissolving the expectancy versus conditioning debate. Psychological Bulletin, 130(2), 324–40.
Strickland, T., Lin, K., Fu, P., Anderson, D., Zheng, Y. (1995). Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biological Psychiatry, 37(5), 325–30.
Sumathipala, A., Siribaddana, S. H., Bhugra, D. (2004). Culture-bound syndromes: the story of dhat syndrome. British Journal of Psychiatry, 184, 200–9.
Takahashi, R. (1979). Lithium treatment in affective disorders: therapeutic plasma level. Psychopharmacology Bulletin, 15, 32–5.
Tooby, J., Cosmides, L. (1992). The psychological foundations of culture. In: J. H. Barkow, L. Cosmides and J. Tooby (eds) The Adapted Mind: Evolutionary Psychology and the Generation of Culture. Oxford: Oxford University Press. Chapter 1.
Walsh, B. T., Seidman, S. N., Sysko, R., Gould, M. (2002). Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association, 287(14), 1840–7.
Wang, S. L., Huang, J. D., Lai, M. D., Liu, B. H., Lai. M. L. (1993). Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clinical Pharmacology & Therapeutics, 53, 410–18.
Westermeyer, J. (1989). Somatotherapies. In J. H. Gold (ed.) Psychiatric Care of Migrants: A Clinical Guide. Washington DC: American Psychiatric Press, 139–68.
Yang, Y. Y. (1985). Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatrica Scandinavia, 71, 171–5.
Yu, X. (2008). Complementary medicines in mental disorders. In C. H. Ng, K.-M. Lin, B. S. Singh and E. Chiu (eds) Ethno-Psychopharmacology: Advances in Current Practice. Cambridge: Cambridge University Press, Chapter 9.
Zhou, H. H., Adedoyin, A., Wilkinson G. R. (1990). Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clinical Pharmacology and Therapeutics, 48(1), 10–17.
Zhou, S. F., Liu, J. P., Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 41(2), 89–295.
Ziegler, V. E., Biggs, J. T. (1977). Tricyclic plasma levels: effects of age, race, sex and smoking. Journal of American Medical Association, 238, 2167–9.